en · de · es · fr · pt
tb-500-notes.peptides7250.com › Wiki › Thymosin Beta-4 Fragment Background — Research Overview

Thymosin Beta-4 Fragment Background — Research Overview

By Editorial Desk · published 2025-12-02 · last reviewed 2026-01-02 · Wiki

prohibited substance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-01-02. Numbers and descriptions here follow the published literature rather than marketing material.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Related pages on this site

Detection, Stability, and Regulatory Status

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Background from the literature

A later vertebrate study identified protein tyrosine phosphatase receptor F (PTPRF), a member of the LAR family, as a conserved cognate receptor for the glucogenic actions of asprosin. In zebrafish, two Ptprf paralogs (ptprfa/b) are expressed in liver, bind asprosin with nanomolar affinity, and are required for asprosin-induced hyperglycemia and upregulation of gluconeogenic genes; soluble Ptprf ligand-binding domains neutralize the glucogenic effects and lower basal glucose, while ptprfa/b knockout fish show hypoglycemia and a blunted response to asprosin but normal responses to glucagon. In mice, PTPRF is expressed in liver and binds asprosin; Ptprf-deficient animals exhibit impaired asprosin-induced glucose production and reduced hepatic G6pc and Pck1 induction, and Ptprf deletion improves glucose tolerance without altering Olfr734 expression. Mechanistically, the same study showed that asprosin promotes insulin receptor and Akt dephosphorylation via PTPRF, counteracting insulin's suppression of gluconeogenesis and suggesting that chronic asprosin–PTPRF signaling contributes to hepatic insulin resistance. Several other independent studies have confirmed asprosin's glucogenic function.

In 2008, Calderón signed the Mérida Initiative with the United States, which provided funding, training, and intelligence, and allowed U.S. personnel to operate in Mexico in advisory and intelligence-sharing capacities. By 2011, the Mexican Armed Forces had captured 11,544 people who were believed to have been involved with the cartels and organized crime. In the year prior, 28,000 individuals were arrested on drug-related charges. In October 2012, Mexican Navy forces killed Heriberto Lazcano, leader of Los Zetas, in a shootout in Sabinas, Coahuila, after gunmen attacked their patrol. The operation came just hours after the capture of another senior Zeta, Salvador Alfonso Martínez Escobedo. Lazcano's death is viewed as the most significant cartel leader killing in Calderón's administration. It strengthened the Navy's standing, allowed Miguel Treviño Morales to take control of Los Zetas, and ultimately benefited Joaquín "El Chapo" Guzmán, whose Sinaloa Cartel sought to dominate the Nuevo Laredo smuggling routes.

== Methodology == Operando spectroscopy is a class of methodology, rather than a specific spectroscopic technique such as FTIR or NMR. Operando spectroscopy is a logical technological progress in situ studies. Catalyst scientists would ideally like to have a "motion picture" of each catalytic cycle, whereby the precise bond-making or bond-breaking events taking place at the active site are known; this would allow a visual model of the mechanism to be constructed. The ultimate goal is to determine the structure-activity relationship of the substrate-catalyst species of the same reaction. Having two experiments—the performing of a reaction plus the real-time spectral acquisition of the reaction mixture—on a single reaction facilitates a direct link between the structures of the catalyst and intermediates, and of the catalytic activity/selectivity. Although monitoring a catalytic process in situ can provide information relevant to catalytic function, it is difficult to establish a perfect correlation because of the current physical limitations of in situ reactor cells. Complications arise, for example, for gas phase reactions which require large void volumes, which make it difficult to homogenize heat and mass within the cell. The crux of a successful operando methodology, therefore, is related to the disparity between laboratory setups and industrial setups, i.e., the limitations of properly simulating the catalytic system as it proceeds in industry.

Granola bars are made of granola, muesli or cereal, typically including oat flakes, vegetable fats or oils, and some type of sweetener. Many granola bars contain additional ingredients such as nuts, dried fruits, and seeds. They become popular in the 1960s as part of the counterculture Hippie movement.

Sources: en.wikipedia.org

Reference notes

Australia: Electronic Travel Authority (ETA) eVisitor programme East African Community: From February 2014, Kenya, Rwanda and Uganda issue an East African Tourist Visa. Hong Kong: Mainland Travel Permit for Taiwan Residents India: India permits nationals of most jurisdictions to clear border controls using an e-visa. Kenya: From 1 January 2021, Kenya solely issues e-visas, and physical visas are no longer available. New Zealand: Electronic Travel Authority (NZeTA) North America: Canadian ETA, US Electronic System for Travel Authorisation Pakistan: Pakistani ETA. South Korea: eligible visa-free visitors must obtain Korea Electronic Travel Authorization (K-ETA). Sri Lanka: Sri Lankan ETA Qatar: ETA needed for up to 30 days. United Kingdom: Electronic Visa Waiver, or EVW The Nationality and Borders Bill, before the parliament in Spring 2022, includes a proposal to introduce the Electronic Travel Authorisation system for all non-UK and Irish citizens.

Similarly, researchers from the Technical University of Munich and LMU Munich have developed a method to have T-cells target tumor cells by using antigen coated DNA origami. The researchers developed a method to create chassis known as programmable T-cell Engagers (PTEs) which are DNA origami structures that can be configured to bind to user-defined target cells and T-cells based on which antigens are coated on the surfaces of the nanostructure. The in vitro results show that after 24 hours of exposure 90% of the tumor cells were destroyed. Meanwhile, in vivo testing showed that their PTEs were capable of binding to the target proteins for several hours which validates the mechanism they designed.

== Career == After completing his postdoctoral fellowship in France, in 1969, Watson returned the United States and held a position as an Assistant Professor in the Department of Pharmacology at Vanderbilt University, in Nashville Tennessee. Jack was promoted to Associate Professor with tenure in 1974. While at Vanderbilt, Watson published the first edition of Introduction to Mass Spectrometry: Biomedical, Environmental, and Forensic Applications in 1976. It was the first book to include journal titles as part of the cited literature. Harold G. (Harry) Walsh had just joined the ACS as director of the Short Course program. Walsh approached Watson and asked him to teach a course. Walsh also asked that Watson select someone from the mass spectrometry industry to co-teach the course. Watson had met O. David Sparkman, an American working for the French Gas Chromatography/Mass Spectrometry company, Riber, in Paris, a few months earlier. Watson asked Sparkman to contribute to the data systems part of the course. They taught the first session at the annual Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy in the Spring of 1978. They taught the course two more times that year at the annual ACS meetings and continued teaching into the first decade of the next millennium. In 1980 Watson accepted a joint appointment in the Departments of Biochemistry and Chemistry at Michigan State University, East Lansing Michigan. He also became the director (Principal Investigator) of the National Institutes of Health (NIH) P41 Regional Resource in Mass Spectrometry at MSU.

Sources: en.wikipedia.org

Notes from published material

== Interaction with juvenile hormone == Juvenile hormone is synthesised in the corpora allata. In every insect tested, at least one of the three types of Allatostatin inhibits the biosynthesis of juvenile hormone. This is achieved by paracrine release of Allatostatin from neurons in the brain which terminate in the corpora allata. The signal is transduced by GPCR receptors, but the intracellular pathway is not yet known. Other amine and neuropeptide neurotransmitters may also inhibit juvenile hormone biosynthesis.

== Constitutional status == Article 1 (1) of the Indian constitution says that India shall be a "Union of States", which is elaborated under Parts V (The Union) and VI (The States) of the constitution. Article 1 (3) says the territory of India comprises the territories of the states, the union territories and other territories that may be acquired. The concept of union territories was not in the original version of the constitution, but was added by the Constitution (Seventh Amendment) Act, 1956. Article 366(30) also defines union territory as any union territory specified in the First Schedule and includes any other territory comprised within the territory of India but not specified in that schedule. In the constitution wherever it refers to territories of India, it is applicable to the whole country including union territories. Where it refers to only India, it applies to all states only but not to union territories. Thus, citizenship (part II), fundamental rights (part III), Directive Principles of State Policy (part IV), Judiciary role, the Union Territories (part VIII), Article 245, etc. apply to union territories as it refers specifically to territories of India. The executive power of the Union (i.e. union of states only) rests with the president of India. The president of India is also the chief administrator of union territories as per Article 239. The union public service commission's role does not apply to all territories of India as it refers to India only in Part XIV.

=== Bogorad's syndrome === Bogorad's syndrome, also known as "crocodile tears syndrome", is an uncommon consequence of nerve regeneration subsequent to Bell's palsy or other damage to the facial nerve. Efferent fibers from the superior salivary nucleus become improperly connected to nerve axons projecting to the lacrimal glands, causing one to shed tears (lacrimate) on the side of the palsy during salivation while smelling foods or eating. It is presumed that this would cause salivation while crying due to the inverse improper connection of the lacrimal nucleus to the salivary glands, but this would be less noticeable. The condition was first described in 1926 by its namesake, Russian neuropathologist F. A. Bogorad, in an article titled "Syndrome of the Crocodile Tears" (alternatively, "The Symptom of the Crocodile Tears") that argued the tears were caused by the act of salivation.

Casein-based glues are formulated from casein, water, and alkalis (usually a mix of hydrated lime and sodium hydroxide). Milk is skimmed to remove the fat, then the milk is soured so that the casein is precipitated as milk curd. The curd is washed (removing the whey), and then the curd is pressed to squeeze out the water (it may even be dried to a powder). The casein is mixed with alkali (usually both sodium and calcium hydroxide) to make glue. Glues made with different mixes of alkalis have different properties. Preservatives may also be added. They were popular for woodworking, including for aircraft, as late as the de Havilland Albatross airliner in 1939. Casein glue is also used in transformer manufacturing (specifically transformer board) due to its oil permeability. Elmer's Glue-All, Elmer's School Glue and many other Borden adhesives were originally made from casein. While one reason was its non-toxic nature, a primary factor was that it was economical to use. Towards the end of the 20th century, Borden replaced casein in all of its popular adhesives with synthetics like PVA. While largely replaced with synthetic resins, casein-based glues still have a use in certain niche applications, such as laminating fireproof doors and the labeling of bottles. Casein glues thin rapidly with increasing temperature, making it easy to apply thin films quickly to label jars and bottles on a production line.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

Network